Phase I Dose-Escalation Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Patients With Advanced Solid Tumors With Neuroendocrine Features
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 May 2018
At a glance
- Drugs NTX 010 (Primary)
- Indications Carcinoid tumour; Neuroendocrine tumours
- Focus Adverse reactions
- Sponsors NeoTropiX
- 02 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 14 Jun 2006 New trial record.